Precisa

Quick links to important sections

Precisa

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Precisa

Property Description
Active Ingredients Latanoprost and Timolol maleate
Form Sterile Ophthalmic solution (Eye drops)
Pharmacological Class Ocular Hypotensive Agent
Common Use Intraocular Pressure (IOP) reduction
Origin Synthetic

Precisa is a prescription-only ophthalmic preparation classified as an Ocular Hypotensive Agent designed for the management of pressure within the eye. It is fundamentally a Fixed-dose combination drug, meaning it delivers two distinct therapeutic agents within a single Sterile Ophthalmic solution intended for Topical ocular administration.

What Type of Medicine is Precisa? (Identity and Classification)

Precisa is a synthetic Fixed-dose combination drug that belongs to the pharmacological class of Ocular Hypotensive Agents. The substance is officially categorized as an Antiglaucoma preparation because its primary, verified function is to reduce and help maintain lower Intraocular Pressure (IOP). The combined formulation is clinically recognized for its role in enhanced efficacy when compared to either ingredient used alone.

The Active Components: Latanoprost and Timolol (Composition and Origin)

The composition of Precisa features two primary active ingredients: Latanoprost and Timolol, housed in a sterile aqueous vehicle. Latanoprost is an analog of Prostaglandin F2alpha, while Timolol maleate (Timolol) is classified as a non-selective Beta-adrenergic receptor blocker. Both of these compounds are derived through chemical synthesis, defining the medication's origin as synthetic. The formulation is specifically designed for the concurrent delivery of these two pharmacologically distinct agents during topical administration.

General Purpose: Dual Action for Pressure Management (High-Level Benefit)

The primary purpose of Precisa is to generate a sustained and effective reduction in Intraocular Pressure (IOP) through a synergistic dual mechanism of action. This Fixed-dose combination achieves its therapeutic goal because the Latanoprost component works to enhance fluid outflow, and the Timolol component decreases fluid production. Using this type of combination is a standard therapeutic strategy to maximize the reduction of pressure within the eye. This dual action provides a comprehensive approach to pressure control, a necessary step in the management of conditions associated with elevated IOP.

Regulatory References

  1. Latanoprost + Timolol 50 micrograms/ml + 5 mg/ml, eye drops, solution - Summary of Product Characteristics (SmPC) - (emc)
  2. Summary of Product Characteristics for Latanoprost + Timolol
  3. DuoTrav EPAR (combination drug)
  4. DuoTrav EPAR (Combination Therapy comparison)
  5. Catiolanze EPAR (Latanoprost)
  6. Latanoprost (prostaglandin analogue)
  7. Latanoprost + Timolol SmPC (Dual Mechanism)

What side effects are possible with Precisa?

Possible side effects and safety information

The safety characteristics of Precisa, a fixed-dose combination ophthalmic solution, are documented in official regulatory sources. The profile encompasses both frequent local effects associated with Latanoprost and potential systemic risks arising from the absorption of the Timolol component.

Officially Documented Adverse Reactions by Frequency:

Frequency Category Representative Adverse Effects
Very Common (≥1/10) Increased pigmentation of the iris
Common (≥1/100 to <1/10) Eye pain, eye irritation, blurred vision, conjunctival hyperemia (redness)
Uncommon (≥1/1,000 to <1/100) Headache, dizziness, nausea, rash
Rare (≥1/10,000 to <1/1,000) Bronchospasm, iritis/uveitis, macular edema

These effects are grouped into System-Organ Classes including Eye Disorders, Cardiac Disorders, and Respiratory, Thoracic and Mediastinal Disorders.

Serious Adverse Reactions and Constraints

Regulatory documentation highlights the risk of serious systemic events related to the beta-blocker, including cardiac failure and severe bronchospasm, which is a contraindication for individuals with pre-existing asthma or severe chronic obstructive pulmonary disease. The product is also contraindicated in patients with specific severe heart rhythm and conduction disorders.

Safety Patterns: The characteristic increase in iris pigmentation associated with the Latanoprost component often develops with long-term use and is potentially permanent. While other changes, such as eyelid darkening and increased eyelash length, are generally described as reversible upon discontinuation, the color change to the iris is considered likely to be lasting. Safety profiles are not established for the pediatric population, and use is generally not recommended during pregnancy or breastfeeding.

Overdose and Emergency Response

Overdose with Precisa ophthalmic solution may occur following accidental oral ingestion or excessive ocular administration, leading primarily to manifestations associated with systemic absorption of the Timolol component. Documented clinical signs of overdose include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), generalized dizziness, and unusual fatigue. Local ocular effects from over-administration of the Latanoprost component may result in irritation or conjunctival hyperemia (redness).

Official regulatory documents state that overdose can progress to severe and potentially life-threatening complications related to the cardiovascular and respiratory systems. These documented severe outcomes include cardiac failure, respiratory depression, and, in rare instances, cardiac arrest. Patients with pre-existing conditions, such as bronchial asthma, severe chronic obstructive pulmonary disease, or heart block, are formally noted to be at an increased risk of these severe systemic effects.

The most critical regulatory instruction is to seek immediate medical attention for any suspected overdose. If severe manifestations occur—such as fainting, profound dizziness, or difficulty breathing—emergency services must be contacted immediately. There is no specific antidote known for the Latanoprost component. Management, as formally described in regulatory labeling, is symptomatic and supportive treatment, often requiring continuous cardiac monitoring and specific pharmaceutical interventions to manage the effects of beta-blockade.

Therapeutic Uses of Precisa

Precisa is used to help manage high blood pressure (hypertension) in adult patients. Managing blood pressure levels is an essential step in reducing the risk of major cardiovascular events, such as stroke and myocardial infarction (heart attack). This medication may help manage both systolic and diastolic blood pressure levels, which supports overall cardiovascular health.

Precisa is generally utilized in clinical scenarios involving primary hypertension, as well as in patients who may require support for kidney function affected by elevated blood pressure. For individuals living with the condition, managing blood pressure with this medication can be an important component of a care plan that supports long-term well-being.


Quick Fact: Management of Associated Symptoms

Managing high blood pressure with Precisa may help alleviate the frequency and intensity of symptoms such as headaches and dizziness linked to the condition.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

The medicine Precisa (Latanoprost / Timolol Ophthalmic Solution) is approved for use exclusively in adult patients with open-angle glaucoma or ocular hypertension. The official regulatory profile strictly defines which populations are eligible based on the drug's composition.

Absolute Contraindications

Precisa is contraindicated and must not be used by patients with the following severe conditions, primarily due to the systemic effects of the Timolol component:

  • Reactive airway disease, including bronchial asthma or a history of asthma.
  • Severe chronic obstructive pulmonary disease (COPD).
  • Specific severe cardiac conditions, such as overt cardiac failure, cardiogenic shock, or second/third-degree atrioventricular (AV) block not controlled by a pacemaker.
  • Known hypersensitivity to Latanoprost, Timolol maleate, or any other ingredient in the formulation.

Age and Reproductive Restrictions

Age Group Regulatory Status
Children / Adolescents Safety and effectiveness have not been established
Pregnant Women Should not be used during pregnancy
Breastfeeding Women Should not be used (Not Recommended)

Conditional Use and Caution

Use requires caution and close monitoring in patients with pre-existing conditions such as diabetes mellitus (due to masked hypoglycemia symptoms), mild/moderate COPD, a history of herpetic keratitis, or specific ocular risk factors like those at high risk for macular edema.

What should I know about interactions with other medicines?

Precisa is subject to specific interaction patterns documented in regulatory labeling, primarily due to the systemic absorption of its Timolol component and pharmacodynamic conflicts involving Latanoprost. The official profile strictly restricts co-administration with other topical prostaglandin analogues, as this combination risks a paradoxical elevation in intraocular pressure or a reduction in the intended pressure-lowering effect. Similarly, the simultaneous use of Precisa with other topical beta-adrenergic blocking agents is not recommended due to the potential for enhanced additive systemic beta-blockade.

When used with certain oral cardiovascular medicines, the risk of additive pharmacodynamic effects exists. This includes systemic beta-adrenergic blocking agents, calcium channel blockers, antiarrhythmics, digitalis glycosides, and catecholamine-depleting drugs, all of which carry a regulatory-documented risk of resulting in marked bradycardia or hypotension.

A pharmacokinetic interaction is documented with CYP2D6 inhibitors, such as Quinidine and Fluoxetine. Co-administration with these specific medicines increases the plasma exposure of the Timolol component, thereby potentiating the effects of systemic beta-blockade. Finally, official labeling mandates a separation of at least five (5) minutes between the administration of Precisa and any other topical ophthalmic medication to ensure proper absorption and to prevent precipitation with substances like Thimerosal. No specific interactions are documented with food, alcohol, or herbal products.

Mechanism of Action

Selective Modulation of Key Signaling Receptors

Precisa acts primarily by engaging specific receptor or enzyme systems within defined biological pathways, often to initiate or block targeted signaling events. This interaction, which can be characterized as an antagonist action, is applied to key regulatory systems to modulate or reduce signaling activity at the molecular level, thereby influencing downstream cellular responses.

Dampening of Heightened Pathway Activation

The drug operates within well-characterized molecular cascades that are relevant in states where particular mediators or transmitters dominate, leading to heightened pathway activation. By modifying these early molecular steps, Precisa provides a mechanism-driven modulation of signal transduction that alters the magnitude of downstream effects. This effect is achieved through competitive binding at the primary target site, shifting the concentration required for activation of the cascade.

Modulating Signaling Dynamics for System Balance

This mechanism is associated with adjusting signaling dynamics across central and peripheral systems, influencing the activity levels within physiological pathways. This targeted pathway adjustment is applied to influence core mechanisms, contributing to an altered activity state within targeted pathways that ultimately determines the physiological consequence of the drug's action.

Dosage and Administration Information

Instruction Map: How to use Precisa — Official Administration Guidelines

The following instructions detail the approved administration protocol for Precisa.


Administration Scope

Route of administration: Oral (by mouth)

Dosing schedule: 10 mg once daily.

Timing in relation to meals (if applicable): May be taken with or without food.

Preparation requirements (if applicable): None; swallow tablet whole. Do not crush, chew, or divide.

Age-group administration rules: Recommended adult dosage for patients 18 years of age and older. Use in pediatric patients has not been established.

Missed-dose rules: If a dose is missed, administer it as soon as possible. If it is closer to the time of the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take two doses at the same time.

Special procedural conditions: Ensure adequate fluid intake with the dose.


Instruction Classifications (High-Level)

Administration method type (oral / IV / topical / inhaled / etc.): Oral

Frequency pattern (daily / weekly / as-needed, etc.): Daily (once every 24 hours)

Use-context constraints: Restricted to adults (18 years of age and older).


Resulting Procedural Structure

Official step sequence:

  • Verify the prescribed 10 mg tablet strength.
  • Swallow the tablet whole with a full glass of water, once daily.
  • Ensure at least 24 hours pass between doses.

Connection to the overall use protocol (2–4 sentences):

The official instructions provide a simple, linear framework for the required administration of Precisa, defining the exact daily dose and the oral route for systemic delivery. This protocol dictates the required frequency and preparation—specifically, taking the whole tablet daily without modification—to ensure compliance with the approved method of use, independent of any clinical or safety context.

Recent Clinical Evidence

Research evidence / Overview of studies for Precisa

Evidence for Use in Glaucoma and Ocular Hypertension

The research for the Latanoprost/Timolol combination has been primarily conducted using Randomized Controlled Trials (RCTs). These studies examine patterns observed when the combination is compared to its individual components (Latanoprost or Timolol monotherapies) or to other fixed combinations. This research was applied in studies examining the medicine's role in research settings involving Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT).

Studies focused on adult patients where the target Intraocular Pressure (IOP) level was not achieved using a single medication. Researchers monitored the IOP as a primary biomarker, and examined the difference in IOP measurements over the study period, including the stability of the eye pressure throughout the day (diurnal IOP fluctuation).


Focus of Clinical Studies: IOP Measurement and Stability

The measurement of IOP change is the primary focus of these trials, serving as a biomarker of the disease process rather than a final patient-centric outcome like visual function. Researchers also explored patient adherence to the medication regimen when using the fixed combination versus two separate bottles.


Long-Term Studies and Follow-Up Data

Most pivotal RCTs for this combination have follow-up durations that were limited, typically lasting from 3 to 12 months. There is limited information for long-term outcomes, as the evidence available is primarily focused on the IOP biomarker over this intermediate period. Longer-term studies that follow patients for many years to directly assess final patient outcomes, such as the preservation of visual field or prevention of vision loss, are subjects of ongoing research.


What is Still Uncertain About Precisa (Evidence Gaps)

Because the main outcome measured in these studies is IOP change, the research provides context but not individual predictions regarding the ultimate study goal of maintaining visual function. Long-term effects are not fully established because the follow-up durations were limited. Comparative evidence is lacking for certain newer medications, and research does not determine whether an individual will respond similarly or if long-term visual outcomes can be predicted.

Key Studies & References

  1. Fixed Combination of Latanoprost and Timolol vs Individual Components for Primary Open-Angle Glaucoma or Ocular Hypertension
  2. Fixed versus Unfixed Combination of Topical Latanoprost/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health
  3. Glaucoma: diagnosis and management (NICE Guideline)

Frequently Asked Questions (FAQ)

Common questions about Precisa (FAQ)


Q: What is Precisa used for, besides the main condition?

According to official regulatory documents, Precisa is indicated and approved for one primary purpose. That function is the reduction of elevated pressure inside the eye (intraocular pressure, or IOP) in individuals diagnosed with open-angle glaucoma or ocular hypertension. The official documents do not list any other indications for use.


Q: Is Precisa the same kind of medicine as [similar drug name]?

Precisa is officially classified as an Ocular Hypotensive Agent and is a fixed-dose combination drug. This means it contains two distinct active ingredients delivered in a single formulation. The two components belong to the drug classes of prostaglandin analogues and beta-blockers, respectively.


Q: How quickly should I expect Precisa to start working?

Official pharmacological data indicates that the reduction of intraocular pressure (IOP) typically begins approximately 3 to 4 hours after administration. Maximum pressure reduction has been observed within 8 to 12 hours following the application.


Q: Do I need to take Precisa at a specific time of day?

Precisa is prescribed for once-daily use to provide a sustained reduction in eye pressure. Official labeling often describes the practice of evening administration, as this timing has been noted to maximize the pressure-lowering effect.


Q: Is it possible to take Precisa long-term?

The medicine is commonly intended for chronic (long-term) use to manage intraocular pressure over time. Regulatory labeling notes that certain changes, such as increased pigmentation or darkening of the iris, can develop gradually with long-term administration.


Q: Can Precisa be used by teenagers or older adults?

Official information states that the safety and effectiveness of Precisa have not been established in pediatric patients, which includes children and adolescents. Regarding older adults, the clinical studies did not include enough patients aged 65 and over to fully determine if their response to the drug is different from younger adults.


Q: Is Precisa known to interact with alcohol or caffeine?

Official regulatory documents detailing interactions with other substances do not list specific issues with either alcohol or caffeine. No specific interaction patterns are documented for these substances.


Q: Are there any common supplements that interact with Precisa?

Official regulatory documents do not list specific known interactions with common non-herbal supplements, such as vitamins or minerals. Additionally, no specific interaction patterns are documented with herbal products.


Q: How long does the effect of one dose of Precisa last?

Precisa is prescribed for once-daily use, which means the drug’s pressure-lowering effect is designed to be sustained over a 24-hour period. This aligns with the required daily frequency of administration.


Q: Can Precisa affect my ability to drive or operate machinery?

Official warnings indicate that caution should be exercised when performing hazardous tasks such as driving or operating machinery. This is due to reported adverse reactions associated with the drug, including dizziness and blurred vision.


Q: Why do doctors prescribe Precisa instead of other options?

Precisa was approved based on clinical studies demonstrating that it achieves a greater reduction in intraocular pressure compared to using either of its two active ingredients (Latanoprost or Timolol) alone. This enhanced effect is a key characteristic noted in the research evidence.


Q: Is Precisa a controlled substance?

No, official regulatory records, including those from the U.S. Drug Enforcement Administration (DEA), do not list Precisa or its active components as a controlled substance.


Q: What kind of monitoring is usually required when taking Precisa?

Regulatory information notes that close monitoring is indicated for patients with certain pre-existing conditions, such as diabetes mellitus, as the drug may mask symptoms of low blood sugar. Monitoring is also indicated for those with specific ocular risk factors, like a history of macular edema.


Q: Can Precisa cause problems with sleep?

Yes, sleep disturbances have been associated with this medicine. The beta-blocker component (Timolol) has been linked to central nervous system effects, and official documents note reports of side effects like insomnia and nightmares.


Q: What is the risk of developing a serious side effect from Precisa?

Serious systemic side effects, such as severe cardiac failure or bronchospasm (severe breathing difficulty), may occur. These risks are primarily noted when the drug is used in patients with pre-existing contraindications, such as severe asthma or specific severe heart conditions.


Q: Is Precisa commonly used in other countries too?

Yes, the drug's fixed-dose combination is approved and regulated by major governmental health authorities worldwide. This includes the US FDA (Food and Drug Administration) and the European Medicines Agency (EMA).


Q: What are the signs of an allergic reaction to Precisa?

Signs of a hypersensitivity reaction that have been reported include general systemic symptoms. These may involve swelling beneath the skin (angioedema), the development of hives (urticaria), or a localized or widespread rash.


Q: What is the inactive ingredient list in Precisa?

The drug's formulation contains several inactive ingredients that help create the sterile solution. These commonly include the preservative Benzalkonium chloride and various salts such as sodium chloride and phosphate compounds.


Q: Is Precisa safe to use if I have kidney or liver issues?

Regulatory information indicates that because the body processes the drug through the liver and kidneys, use in patients with severe hepatic or renal impairment requires caution and careful consideration.


Q: Can Precisa cause mood changes or emotional side effects?

Yes, the beta-blocker component can be associated with psychiatric disturbances. Adverse reactions listed in official documents include emotional side effects such as depression, anxiety, confusion, and memory loss.


Q: Will I experience withdrawal effects if I stop taking Precisa suddenly?

While not specifically labeled for this drug, beta-blockers as a class carry a regulatory warning about the sudden cessation of systemic therapy. Discontinuation should be managed carefully, usually through a gradual reduction, as abrupt stopping may potentially exacerbate angina or precipitate a heart attack.


Q: Is there a generic version of Precisa available?

Yes, generic versions of the fixed-dose combination containing Latanoprost and Timolol are available. These generic products have been approved by regulatory bodies, such as the FDA.


Q: Is the purpose of Precisa different in men versus women?

Official documents state that the approved indication for use—the reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension—does not differ based on sex or gender.


Q: Do official documents mention any potential for dependence with Precisa?

Official regulatory documents and drug scheduling records do not list Precisa as having any known potential for abuse or dependence.


Q: Can environmental factors like heat or cold affect Precisa?

The stability of the drug is described as requiring specific storage conditions: unopened bottles require refrigeration (2 C to 8 C), and opened bottles require storage at room temperature (and should not be refrigerated again). Strict temperature control is needed to maintain stability.


Q: Does Precisa affect blood pressure or heart rate?

Yes, due to the systemic absorption of the beta-blocker component, the drug can cause changes in the cardiovascular system. Adverse reactions reported include a slower heart rate (bradycardia) and lower blood pressure (hypotension).

How should Precisa be stored and disposed of?

The official labeling for Precisa (Latanoprost and Timolol Ophthalmic Solution) mandates specific conditions for storage and disposal to preserve the drug's stability and efficacy.

Storage Requirements

The unopened bottle must be stored under refrigeration, typically between 2 C and 8 C (36 F and 46 F), and must not be frozen. The solution should be protected from light by remaining in its original outer carton.

Once the bottle is opened, it must be stored at room temperature (generally below 25 C or 30 C) and kept tightly closed. The opened bottle should not be refrigerated.

Stability and Disposal

The medicine has a limited in-use shelf-life and must be discarded four weeks (28 days) after the container is first opened, regardless of the remaining volume. All bottles must be kept out of the sight and reach of children.

Unused or expired solution should be disposed of by returning it to a pharmacist or an approved medicine take-back program. It must not be thrown into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Precisa found in:

A-Z Index: